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ABSTRCT OF DISSERTATION

THE ROLE OF ANGIOTENSINOGEN IN ATHEROSCLEROSIS AND OBESITY
Angiotensinogen is the only known precursor in the renin-angiotensin system, a
hormonal system best known as an essential regulator of blood pressure and fluid
homeostasis. Angiotensinogen is sequentially cleaved by renin and angiotensinconverting enzyme to generate angiotensin II. As the major effector peptide, angiotensin
II mainly function through angiotensin type 1 receptor.
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and
more recently renin inhibitors are widely known as the 3 classic renin-angiotensin system
inhibitory drugs against hypertension and atherosclerosis. Here, we developed an array
of regents to explore the effects of angiotensinogen inhibition. First, we demonstrated that
genetic deficiency of angiotensinogen not only protected against hypercholesterolemiainduced atherosclerosis but also prevented diet-induced obesity. Then we found weekly
intraperitoneal injection of antisense oligonucleotides against angiotensinogen remarkably
surpressed body weight gain in mice fed a western diet, which was absent from classic
renin-angiotensin system inhibition. The suppressed body weight gain was attributable to
diminished body fat mass gain and enhanced energy expenditure. More excitingly,
angiotensinogen antisense oligonucleotides regressed body weight gain on obese mice.
Together, our findings revealed a unique feature of angiotensinogen inhibition beyond
classic renin angiotensin inhibition and demonstrated therapeutic potentials of
angiotensinogen antisense oligonucleotides against hypertension, atherosclerosis, and
obesity.
We also developed an in vivo system to explore the functional consequences of
disrupting a conserved Cys18-Cys137 disulfide bridge in angiotensinogen. The formation
of this disulfide bridge could trigger conformational changes in angiotensinogen, thereby
facilitating renin cleavage of angiotensinogen. It was predicted that the redox-sensitive
disulfide bridge might change the efficiency of angiotensinogen/renin reaction to release
angiotensin II, thus modulate angiotensin II-dependent functions. We determined effects
of the presence and absence of the disulfide bridge on angiotensin II concentrations and
responses in mice expressing either native angiotensinogen or Cys18Ser, Cys137Ser
mutated angiotensinogen in liver via adeno-associated viral vectors. Contrary to the
prediction, disruption of Cys18-Cys137 disulfide bridge in angiotensinogen had no
discernible effects on angiotensin II production and angiotensin II-dependent functions in
mice.
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Chapter One: Literature Review

This chapter is based on a review published in “N Am J Med Sci (Boston). 2011 October
1; 4(4): 183–190”, with Congqing Wu as the first author.

Introduction

The renin-angiotensin system (RAS) is essential for the regulation of blood pressure and
fluid homeostasis. Angiotensinogen (AGT) is the only known precursor of all angiotensin
peptides. Through sequential cleavages by the classic enzymes, renin and angiotensinconverting enzyme (ACE), or enzymes of alternative pathways, AGT gives rise to a
spectrum of angiotensin peptides, with angiotensin (Ang) II being the major effector
peptide that regulates blood pressure and sodium/water homeostasis. Many
components of the renin-angiotensin system including renin and ACE, as well as ang II
and its receptors are well characterized and have been comprehensively studied in
animal models. While much of the basic understanding of AGT has come from research
efforts to define its role in blood pressure regulation, novel pathophysiological functions
of AGT have been discovered in the last two decades, including kidney developmental
abnormalities, atherosclerosis, and obesity. Despite advances in the understanding of
AGT gene and protein functions, some fundamental questions remain unanswered. This
is partially due to the traditional view of AGT as a passive substrate and lack of
pharmacological inhibitors that directly target the protein. Development of many state-ofthe-art techniques including the successful creation of cell-specific deficient mice is
providing new insights into this substrate of the RAS. In this chapter, I summarize the
literature on molecular characteristics of AGT and its pathophysiological features. In light
1

of the recent progress, I emphasize some newly recognized functional features of AGT
other than its regulation on blood pressure. Specifically, I highlight effects of AGT on
atherosclerosis and obesity.

Molecular characteristics of AGT

Gene structure of AGT
The AGT gene in humans and rodents was cloned, mapped and characterized
throughout the 1980s (1-7). It is well conserved among vertebrates (8). Human AGT
gene is a single-copy gene, locating within 20 Mb to the end of the long arm (1q42.2) on
chromosome 1. With 5 exons and 4 introns, it spans 12,063 bp (nucleotide 230,838,274
- 230,850,336) and encodes 485 amino acids. The first exon contains 500 bp of the 5´untranslated region. The second exon codes the 33- amino-acid signal peptide and more
than half of the mature protein. Exon 5 encompasses the C-terminus of the protein as
well as over 600 bp of the 3´-untranslated region (Figure 1.1).

The AGT gene in mice is similar to that of humans in terms of genomic size, gene
structure, and coding exons (encoding 477 amino acids in mice versus 485 amino acids
in humans). It is located on chromosome 8 within only 4.6 Mb to the telomere, which
makes genetic manipulations of the AGT gene in mice an arduous task.

Protein characteristics of AGT
Human AGT is a heterogeneous plasma glycoprotein, mainly synthesized in
hepatocytes. After removal of the 33-amino-acid signal peptide, the 452-amino-acid
mature protein, with the first 10 amino acids corresponding to AngI is secreted into
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plasma. The heterogeneity of plasma AGT is primarily due to variable glycosylation (9).
Human AGT protein contains four putative sites for N-linked glycosylation (Asn-X-Ser/
Thr): Asn14, Asn137, Asn271 and Asn295. An in vitro site-mutagenesis study
demonstrates that all four sites can be glycosylated, with preference at Asn14 and
Asn271 (9). Asn14 is close to the renin cleavage site (Leu10-Val11), and its
glycosylation has been demonstrated to lower the affinity of AGT for renin (9). Asn14
glycosylation is also present in mice, but not in rats. These glycosylation sites appear to
have no critical roles on folding, intracellular trafficking, or secretion of the AGT protein
(9).

Human AGT protein contains four cysteines. Only two of these forming Cys18-Cys138
linkage (Figure 1.1) are conserved across species (9, 10). The crystal structure of
human AGT shows that the formation of Cys18-Cys138 disulfide bridge confers a
conformational change that allows access of renin to its cleavage site of AGT (Figure
1.2). It has been demonstrated that oxidative status of AGT has an impact on the rate of
AGT-renin reaction in vitro (11), which may contribute to preeclampsia. It is unknown
whether this disulfide bridge has similar properties in mouse AGT.

Another noteworthy feature is the species specificity of AGT-renin reaction. For example,
human AGT is not cleaved by mouse renin efficiently (12, 13). While this may be
influenced by an amino acid substitution at the renin cleavage site, Leu10-Val11 bond in
humans versus Leu10-Leu11 bond in mice (13), the mechanism of this unique property
has not been completely unraveled.

The cleavage of intact AGT by renin leads to generation of both AngI and des(AngI)AGT, the remaining residues after removal of AngI that accounts for more than 95% of
3

the AGT protein sequence and maintains a typical serpin folding. The relative
abundance of intact versus des(AngI)-AGT has not been characterized. There is some
evidence that des(AngI)-AGT itself has biological properties that may relate to the serpin
characteristics of the protein (14, 15).

Regulation of AGT
AGT gene expression is under developmental and hormonal controls in a cell typespecific manner (16). It is generally accepted that the predominant regulation of AGT
occurs at the transcriptional level, although some post-transcriptional regulation also
exists (17). AngII has been consistently shown to enhance mRNA stability of AGT and
exert positive feedback on AGT protein production (17-21). AngII upregulates AGT
mRAN in hepatocytes through nuclear factor-kappaB activation (NF-kB) (22), and
increases plasma AGT protein through signal transducer and activator of transcription 3
(STAT3) induced interleukin-6 (IL-6) (21, 23). In our laboratory, we have consistently
observed over 2-fold increase of plasma AGT concentrations in mice with exogenous
AngII infusion (unpublished data). The positive feedback of AngII on AGT is balanced by
its negative feedback on renin, the rate-limiting enzyme in the synthesis of angiotensin
peptides.

Multiple putative cis-acting DNA regulatory elements, including glucocorticoids,
estrogen, and acute phase responsive elements, are located within a region of 1 kb that
is immediately upstream of human AGT gene (2, 6). Dexamethasone administration
leads to striking increases of AGT mRNA abundance in liver and modest increases in
brain (24, 25). However, increases of the AGT protein are much less than the mRNA
increases (25). Estrogen is another positive regulator of AGT synthesis. Plasma AGT
concentrations increase in parallel with estrogen during pregnancy. Synthetic estrogen in
4

oral contraceptive pills also increases plasma AGT concentrations in a dose-dependent
manner (25). In contrast to the direct interactions of glucocorticoids and estrogen on the
5′-region of the AGT gene through their corresponding receptors, thyroid hormones
seem to affect AGT mRNA abundance dependent on a secondary gene or protein, since
their effects can be blocked by cycloheximide, an inhibitor of protein synthesis (25). In
addition, for these 3 hormonal regulations, there are many confounding factors, such as
a malignantly high dose above the physiological concentrations, a certain approach of
administration, or interactions with a secondary gene or protein that complicate the
interpretation of the reported findings (25). Therefore, their roles as primary regulators of
AGT require further examination.

Tissue and cellular distribution of AGT
AGT is promptly secreted from cells into extracellular compartments (26). Therefore, the
distribution of AGT synthesis is more commonly determined by mRNA rather than
protein abundance. AGT mRNA has been consistently detected in many tissues such as
liver, adipose, brain, heart, kidneys, and vessels (27-30). It has also been identified in
spinal cord, lungs, adrenal glands, large intestine, stomach, spleen, and ovaries with low
or variable abundances (24, 30). While most AGT mRNA is found in adult liver, it may be
present mainly in adipose tissues, brain, and kidneys at embryonic stage. AGT
production rises remarkably after birth and reaches adult level within 24 hours (31).

At cellular level, besides hepatocytes, it is widely accepted that adipocytes, proximal
tubule epithelial cells, and astrocytes are AGT synthesizing cells (29, 32, 33). Among all
extra-hepatic tissues synthesizing AGT, only adipose tissue has been shown to have an
impact on plasma AGT concentrations using an adipocyte-specific AGT deficient mouse
model (34). On the other hand, liver-specific deletion of a floxed human AGT transgene
5

using adenoviral delivery of Cre recombinase largely diminishes plasma human AGT
concentrations (35). It infers that circulating AGT cannot be compensated by extrahepatic tissues in the absence of hepatocyte-derived AGT. Indeed, liver is not only the
source for plasma AGT but also for AGT in tissues like kidney (36).

Enzymes using AGT as a substrate
While AGT is the only known substrate of all angiotensin peptides, there are many
enzymes that have been identified to use AGT as a substrate (37-40). Renin, a plasma
aspartyl protease, is best known for cleaving AGT into AngI. Indeed, AGT is the only
defined substrate for renin (41). As AGT is the only precursor and AGT-renin reaction is
the rate-limiting step, renin becomes the most effective enzymatic target to inhibit the
renin-angiotensin cascade (42). There is compelling evidence that renal renin is
secreted into plasma to cleave AGT released from liver (38, 43-45). Therefore, this is
considered a systemic pathway to generate angiotensin peptides. There are
controversial findings regarding the local production of renin outside kidneys. While
some studies have reported that kidney-derived renin is the only source to catalyze AGT
locally (45, 46), there is growing evidence that renin can also be synthesized in tissues
other than kidneys or non- juxtaglomerular cells (47-50). In addition to renin, many other
enzymes such as cathepsin D, cathepsin G, kallikrein, pepsin, tissue-plasminogen
activator, tonin, and trypsin have been demonstrated to convert AGT into either AngI or
AngII (39, 40, 51, 52). These enzymes are abundant in tissues or some cell types, which
has led to speculation that these enzymes may impact local generation of angiotensin
peptides. However, most enzymes require an acidic environment (pH range 4–7) to
actively catalyze AGT (40). Currently, the physiological significance of these enzymes
using AGT as a substrate in vivo has not been established.

6

Plasma concentrations of AGT
AGT concentrations in human plasma are approximately 1 μM or 60 μg/ml (28 - 71
μg/ml) (53). This is close to the Michaelis-Menton constant (KM) of human renin (1.25
μM) (54). This indicates both AGT and renin concentrations are important for the rate of
AngII generation, thus control the tonic activity of the RAS. Mice have much lower
plasma AGT concentrations (≈ 20 - 30 nM or 1216 ± 101 ng/ml in C57BL/6 strain), which
are similar in rats (55). It is not clear why plasma AGT concentrations could differ by
over one order of magnitude between humans and rodents.

There is no standard method for measuring AGT protein concentration. Two
approaches, indirect enzymatic assays and direct radioimmunoassay or ELISA, are
currently used by many investigators. Indirect assays measure intact AGT through
equivalent AngI released from the cleavage of AGT by renin in a given amount of time.
Direct assay measures total AGT, which consists of both intact AGT and des(AngI)-AGT.
Recently, a simple and sensitive sandwich ELISA kit has been developed to measure
AGT concentrations in both humans and rodents (53, 55). However, this kit does not
distinguish intact AGT from des(AngI)-AGT, which is important when changes in plasma
concentrations of intact AGT are not correlated with that of total AGT. For instance,
neither sodium depletion nor pharmacological inhibition of the RAS affects plasma total
AGT concentrations, although both intact AGT concentrations and des(AngI)-AGT have
significant changes (37, 56).

Plasma and tissue catabolism of AGT
The cleavage of AGT by renin is well known. However, there is a relative paucity of
information of plasma clearance of either intact AGT or des(AngI)- AGT. Using
radioiodinated tracer studies of AGT, the half-life of the protein has been estimated to be
7

5 hours in rats and rabbits (57-59). It is unknown whether intact intact and des(AngI)AGT have similar rates of clearance from plasma.

There is also spare evidence of tissues responsible for the catabolism of AGT. A single
line of evidence displays that the protein is predominantly accumulated in kidney (59).
However, this study was performed with directly radioiodinated proteins in which the
label may not accumulate at the loci of catabolism. More meaningful analysis may be
obtained by the conjugation of radioiodinated residualizing labels to track tissue sites of
AGT catabolism (60).

Pathophysiological features of AGT

Genetic manipulation of AGT in mice
It has been reported that mice overexpressing either rat (61, 62) or human (63, 64) AGT
gene alone do not exhibit any significant phenotype. In contrast, mice carrying both
human AGT and renin genes display pronounced phenotypes including increased blood
pressure, cardiac hypertrophy, and kidney abnormalities (63, 64), providing in vivo
evidences for the species specificity of AGT-renin reaction.

AGT deficient mice have been developed by two laboratories (65, 66). Besides expected
profound reductions in blood pressure, AGT deficient mice also have renal and cardiac
dysfunction. However, pathologies in these two organs are distinct between transgenic
AGT overexpressing mice and AGT deficient mice. While mice with human AGT and
renin transgenes develop nephrosclerosis and cardiac hypertrophy (67), AGT deficient
mice exhibit hydronephrosis and dilated cardiomyopathy (68, 69). These distinct
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pathologies strongly indicate that tight regulation of AGT production is important to
maintain normal blood pressure as well as normal renal and cardiac structures and
functions.

Characteristics of mice with genetic manipulations of AGT are summarized in Table 1.1.
It is speculated that the phenotypic changes in these mouse models are directly related
to the changes of AngII production since the phenotypes in AGT deficient mice are also
observed equivalently in renin, ACE, and combined AT1a and AT1b receptor deficient
mice (70-73). However, exogenous AngII or tissue-specific enhancement of AngII cannot
fully recover the phenotypes in AGT deficient mice (74-76), indicating that AGT may
have both AngII-dependent and AngII-independent functions. In addition, phenotypes in
AGT deficient mice can only be partially rescued by restoring AGT in circulation or one
to multiple tissues (75-80), supporting a theme that this glycoprotein produced in both
systemic and cell-specific manners synergistically contribute to its pathophysiological
functions.

Recently, AGT floxed mice have been developed by two independent research groups
(34, 36). These mice have normal neonatal survival rate and display no gross kidney
abnormalities. Using Cre recombinase trangenic approach under the control of a specific
promoter, AGT floxed mice will provide an optimal approach to understanding the
relationship between AGT and many pathophysiological features as well as the
underlying mechanisms in a cell-specific mode.

Genetic manipulation of AGT in experimental atherosclerosis and obesity
There is compelling evidence that the RAS plays a critical role in the development of
atherosclerosis (81, 82). While many atherosclerosis studies in mice have directly
9

targeted AngII type 1 receptors or either of the two critical enzymes (renin and ACE) (50,
56, 83-87), no study has addressed the role of AGT in atherosclerosis. We have
detected AGT protein in mouse atherosclerotic lesions using immunostaining (85). One
study has reported that mice with human AGT and human renin transgenes in C57BL/6
background had augmented atherosclerosis, compared to the wild type controls, when
fed a high-fat diet for 14 weeks (88). There is no study that has determined the role of
AGT deficiency in atherosclerosis in mice. This is possibly due to their low neonatal
survival rate and severe phenotypes that hamper the breeding of AGT deficient mice to
hypercholesterolemic apolipoprotein E (apoE) or low density lipoprotein (LDL) receptor
deficient mice (68).

Potential associations of AGT with obesity and adipocyte metabolism have been noted
in animal models and in vitro studies. AGT mRNA abundance is increased in adipose
tissues of obese rodents (89-91). Whole body deficiency of AGT leads to a lean
phenotype that is manifested with impaired high fat diet-induced body weight gain,
reduced fat mass, and increased locomotor activity in mice (92, 93). However, these
mice have severe phenotypes that strongly impact the normal development and growth
(64). The unhealthy condition may confound the interpretation of the observed metabolic
phenotypes. In comparison with AGT deficient mice, mice with human AGT and renin
transgenes also exhibit reduced body weight gain compared to their wild type controls,
although these mice have increased tissue and plasma AGT abundance (94). The
paradoxical observations require systematic research on the effects of this gene in
obesity.

Genetic association of AGT with atherosclerosis and obesity in humans
The correlation of AGT gene with human diseases has been investigated primarily
10

through screening single nucleotide polymorphisms (SNPs). The first compelling genetic
evidence of M235T polymorphorism implicating a causal relationship between the AGT
gene and essential hypertension in humans was published in 1992 (95). Since this initial
report, M235T has become the most frequently studied SNP in AGT for hypertension. It
has also been investigated frequently in patients with atherosclerotic diseases. While a
few studies failed to define an association of M235T with atherosclerosis (96), most
studies demonstrated that this polymorphism was associated with atherosclerosis in
different populations (97-100). In addition to M235T, a few studies have also reported
that T174M, another polymorphism in exon 2 of the AGT gene, is related with risk factors
or prevalence of coronary artery disease (101, 102).

Although there is no direct evidence, animal studies and in vitro experiments indicate
that AGT may also play an important role in obesity in humans. Investigations of the
common AGT polymorphisms have shown a significant association of M235T with
obesity in female hypertensive patients in different populations (103-105), although it
failed to display any correlation in males (106).

Currently, genetic polymorphism analyses of the AGT gene are a cardinal approach to
defining an association of this gene with human diseases. Many studies have reported
potential links between SNPs in AGT and atherosclerosis or obesity, although their
causal relationships remain to be established. For both atherosclerosis and obesity, the
reported associations are either modest or only significant in a specific disease state,
either of the two genders, or certain age group within one study. Confounding factors
including small sample size, population heterogeneity, environmental and culture/ethic
differences, multiple disease states, and complex interactions within the gene or with
many other genes, may complicate the interpretation of these polymorphism studies.
11

Therefore, it is important to control for the confounding factors in order to define a clear
link between the AGT gene and atherosclerosis or obesity.

Conclusions and perspectives
The unique position of AGT in the RAS and its distinct features may make this protein an
attractive target in developing effective therapeutic strategies in many human diseases
such as atherosclerosis and obesity. However, despite great efforts in discovering the
molecular mechanisms and clinical relevance of AGT gene and protein functions, some
fundamental questions remain unanswered. These include: (i) Are the effects of AGT on
its pathophysiological phenotypes, in part or in whole, dependent on AngII? (ii) What is
the correlation of AGT produced in local tissues with the circulating pool? And what is
the relative contribution of local versus circulating AGT to its pathophysiological
functions? (iii) What is the fate of des(AngI)- AGT? Is it degraded rapidly after the
release of AngI, or is it biologically functional, independent of the classic RAS? (iv) As
demonstrated by the crystal structure of AGT, Cys18-Cys138 linkage determines the
accessibility of its cleavage site to renin. Is the modulation of this disulfide bond relevant
to the development or progress of its pathophysiological functions? These unanswered
questions provide both challenges and opportunities to explore the mechanisms and
effects of AGT in human diseases. Current advancement of many state-of-the-art
techniques, including reconstructing AGT protein and the availability of cell-specific AGT
deficient mice, provides excellent tools to answer these questions.

Specific aims
To address some of the fundamental questions discussed above, I propose three
specific aims:
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Aim 1: To investigate the role of AGT inhibition in atherosclerosis and obesity (Chapter
two)
Aim 2: To determine the contributions of systemic and local AGT to atherosclerosis and
obesity (Chapter two)
Aim 3: To analyze the structure-function relationship of Cys18-C138 linkage in AGT
(Chapter three)
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Figure 1.1 Schematic Representation of Human AGT Gene and Protein. Human
AGT gene contains 5 exons. Exon 2 encodes the majority of the protein. After removal of
the 33 aa signal peptide, the 452 aa mature AGT is secreted. Cleavage of mature AGT
by renin gives a decapeptide, AngI, and the 442 aa des(AngI)-AGT. AngI is further
cleaved by ACE into AngII. Two cysteines at 18 and 138 form a disulfide bridge (Cys18Cys138) that confers a conformational change allowing access of renin to the AngI
cleavage site of AGT. Diagrams were drawn proportional to actual gene and protein size
based on the University of California Santa Cruz Human Genome Browser Feb 2009
Assembly. UTR: untranslated region; CDS: coding sequences.
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Figure 1.2 Structure of AGT and its complex with renin (adapted from figure 1 of “A
redox switch in angiotensinogen modulates angiotensin release” (11)) a. Stereo image of
human AGT: serpin template in grey and helix A in purple with the A-sheet in brown, the
unresolved reactive loop in dark red, and in dark purple the CD loop containing Cys 138.
The amino-tail is in blue with the new helix A1 and a second helix A2 containing Cys18
(linked in brown to Cys 138); the terminal AngI segment is in green with the renincleavage site shown as green and blue balls. The sequence below (same color coding)
also indicates the subsequent cleavage by ACE releasing AngII. b. the initiating complex
formed by AGT with inactivated (Asp292Ala) renin (left), and on right superimposed on
15

the unreacted form (brown) showing the displacement of the CD loop and the movement
of the aminoterminal peptide (visible to Cys 18), into the active cleft of renin.
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Chapter Two: Angiotensinogen Inhibition Protects Against Atherosclerosis
and Obesity in Mice

This chapter is based on a manuscript in preparation, titled “Angiotensinogen inhibition
prevents and regresses diet-induced obesity in mice”, with Congqing Wu as the first
author.

Figures based on experiments conducted by others are listed here: figure 2.5, 2.6, 2.7,
2.22, 2.33E,F from Hong Lu, figure 2.15 from ISIS, figure 2.16, 2.17, 2.18, 2.21, 2.23,
2.24, 2.33A-D from Deborah A. Howatt and Anju Balakrishnan.

Synopsis

In the renin-angiotensin system, angiotensinogen is sequentially cleaved by renin and
angiotensin-converting enzyme to generate angiotensin II. As the major effector peptide,
angiotensin II mainly function through angiotensin type 1 receptor. Inhibition of the reninangiotensin system using enzyme inhibitors or receptor blockers of the renin-angiotensin
system, such as angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, and more recently renin inhibitors, are known to reduce blood pressure and
atherosclerosis. As expected, we demonstrated that angiotensinogen inhibition by
antisense oligonucleotides had similar protective effects on blood pressure and
atherosclerosis comparable with these classic inhibitory drugs. Unexpectedly, weekly
injection of antisense oligonucleotides against angiotensinogen remarkably slowed body
weight gain in mice fed a western diet. This body weight effect was not observed in
same mouse strain fed same western diet that were administered any of the 3 classic
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renin-angiotensin system inhibitors. The suppressed body weight gain was attributable
to diminished body fat mass gain and enhanced energy expenditure. Genetic deletion of
angiotensinogen, globally or specifically in hepatocytes, recapitulated phenotypes
observed in mice administered angiotensinogen antisense oligonucleotides. More
excitingly, injection of angiotensinogen antisense oligonucleotides regressed body
weight gain on obese mice. Together, our findings revealed a unique feature of
angiotensinogen inhibition beyond classic renin angiotensin inhibition and demonstrated
therapeutic potentials of angiotensinogen antisense oligonucleotides against
hypertension, atherosclerosis, and obesity.

Introduction

The renin-angiotensin system (RAS) regulates blood pressure and fluid homeostasis.
Angiotensinogen (AGT) is the only precursor of this peptide hormone system (107). In
the classic cascade, AGT is cleaved by renin, the rate-limiting enzyme, to release the
inactive AngI. AngI is cleaved by angiotensin-converting enzyme (ACE) to generate
AngII. As the major effector peptide of the RAS, AngII functions predominantly through
AngII type 1 (AT1) receptors.

With the advent of pharmacological agents targeting ACE, AT1 receptors, or renin, RAS
inhibition has become a prominent strategy for hypertension management. The
landmark HOPE trial (108) is the first to demonstrate cardiac benefits of the ACE
inhibitor independent of lowering blood pressure, followed by ONTARGET trial showing
comparable benefits of angiotensin receptor blocker (ARB) (109). Numerous animal
studies have consistently demonstrated anti-atherosclerotic effects of RAS inhibition
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(81). In addition, RAS inhibition has been reported to profoundly improve obesity-related
diseases such as diabetic nephropathy (110).There is no evidence that these 3 classes
of drugs affect body weight in humans. In our recent side-by-side comparison study in
mice, these 3 classes of drugs, inhibiting either enzymes (renin and ACE) or AT1
receptors, equivalently reduces atherosclerosis through AngII-dependent mechanisms
(56). However, none of them has significant effects on body weight (56).

In contrast to extensive studies on the enzymes and receptors of the RAS, effects of
AGT inhibition have not been directly explored due to the lack of pharmacological agents
targeting the AGT protein as well as severe health problems associated with global AGT
deficient mice. AGT gene and protein are well conserved among vertebrates. Human
AGT is mainly synthesized in hepatocytes and secreted into blood, where it is cleaved
by plasma renin or taken up by peripheral tissues. While the first ten amino acids of
secreted AGT correspond to AngI, the remaining residues after the removal of AngI,
des(AngI)-AGT, accounts for nearly 98% of the AGT protein sequence and maintains a
typical serpin folding, suggesting alternative functions other than being a passive
substrate of the RAS. Indeed, a previous study implicates that des(AngI)-AGT has
functions independent of AngII (14).

We have developed both pharmacological and genetic tools to modulate AGT
expression, and demonstrated that AGT inhibition, not only reduces blood pressure and
atherosclerosis, but also increases energy expenditure and confers resistance to dietinduced obesity, which is beyond the classic RAS inhibition.
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Methods

Ethics statement
All animal experiments reported in this part were performed with approval of the
University of Kentucky Institutional Animal Care and Use Committee (University of
Kentucky IACUC protocol number: 2006-0009).

Mouse housing condition and diet
All mice were maintained in individually vented cages (maximally 5 mice per cage) in a
barrier facility (14:10 hour light-dark cycles, ambient temperature of 22°C). Cage
bedding was Teklad Sani-Chip bedding (Cat # 7090A, Harlan Teklad, Madison, WI,
USA). Mice were fed a normal rodent laboratory diet (Diet # 2918, Harlan Teklad) and
provided with drinking water ad libitum from a reverse osmosis system. To induce
hypercholesterolemia or obesity, mice were fed a saturated fat enriched diet (milk fat
21% wt/wt and cholesterol 0.2% wt/wt; Diet# TD.88137; Harlan Teklad). This diet was
developed in 1988 by collaboration between Harlan Teklad and researchers at
Rockefeller University to mimic the nutrient content of fast food in a typical western food
chain (111). It is referred to as western diet. Indirect calorimetry was carried out on a
subset of mice due to equipment capacity.

Development of hypomorphic AGT mice
AGT floxed mice (Figure 2.1) were developed under a contract with InGenious Targeting
Laboratory (Stony Brook, NY, USA) using a construct containing mouse AGT gene with
insertions of 3 loxP sites and 2 FRT sites, and 1 neo cassette as described previously
(34, 112). This construct was electroporated into embryonic stem cells of mouse strain
129 that were subsequently bred in C57BL/6 mice. With the presence of the neo
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cassette, the resulted AGT floxed mice showed reduced AGT expression globally. They
were bred to Ldlr-/- mice to generate hypomorphic AGT mice (hypoAGT) and AGT wild
type mice (AGT+/+) with LDL receptor -/- background.

Development of hepatocyte-specific AGT deficient mice
The breeding strategy to develop mice with hepatocyte-specific deficiency of AGT
(Figure 2.8) included 4 steps: (1) AGT floxed mice were bred to FLPe mice (B6;SJLTg(ACTFLPe)9205Dym/J, Stock # 003800, N2 to C57BL/6 strain, The Jackson
Laboratory, Bar Harbor, ME) to remove the neo cassette inserted in intron 2 of mouse
AGT gene. (2) After removal of the neo cassette, these mice were bred to Ldlr-/- mice
mice (B6.129S7-Ldlrtm1Her/J, Stock # 002207, N13 to C57BL/6 strain, The Jackson
Laboratory) to generate Agtf/f x Ldlr-/- mice. (3) Male mice expressing Cre recombinase
under the control of a hepatocyte-specific albumin promoter (B6.Cg-Tg(Alb-cre)21Mgn/J,
Stock # 003574, N7 to C57BL/6 strain, The Jackson laboratory) were bred to female
Ldlr-/- mice to generate male Alb-cre1/0 mice in the LDL receptor-/- background. (4) Albcre0/0 x Agtf/f x Ldlr-/- females were bred with Alb-cre1/0 x Agtf/f x Ldlr-/- males to generate
hepatocyte-specific AGT deficient mice hepAGT-/-, and their wild type littermates
hepAGT+/+.

RNA isolation and real-time PCR
Total RNA in liver, kidney, adipose tissue, and brain was extracted with RNeasy Mini Kit
(Qiagen), and then reversely transcribed with an iScript™ cDNA Synthesis Kit (Cat#1708891; Bio-Rad, Hercules, CA). Real time PCR was performed to quantify mRNA
abundance using a SsoFast™ EvaGreen® Supermix kit (Cat# 172-5203; Bio-Rad) on a
Bio-Rad CFX96 cycler. Data were analyzed using ∆∆Ct method, normalized to β-actin
abundance. Primers for real-time PCR are listed in table 2.1.
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Measurement of plasma components
Blood samples were collected with EDTA (final concentration at 1.8 mg/ml) and
centrifuged at 400 g for 20 minutes, 4 °C to separate plasma. Before termination, blood
samples were collected using retro-orbital bleeding on conscious mice. At termination,
blood samples were collected using right ventricular puncture after anesthesia (a mixture
of ketamine 100 mg/kg and xylazine 10 mg/kg).
Plasma AGT concentrations were determined using an ELISA kit, as described
previously (55) (Cat # 27413, Immuno-Biological Laboratories Co., Ltd, Takasaki-Shi,
Gunma, Japan).

Plasma total cholesterol concentrations were measured using an enzymatic kit (Cat #
439-17501; Wako Chemicals USA, Richmond, VA).

Drug administration
Alzet mini-osmotic pumps (model 2004; Durect Corporation, Cupertino, CA, USA) were
implanted into LDL receptor -/- male mice at the age of 8 weeks, and replaced every 4
weeks to continuously deliver drugs for a total of 12 weeks (83, 113). Drug doses were
listed as follows: vehicle (PBS); aliskiren 2.5, 12.5 or 25 mg/kg/day; enalapril 0.25, 1.25
or 2.5 mg/kg/day; and losartan 2.5, 12.5 or 25 mg/kg/day. Doses of each drug were
chosen based on estimates that would encompass a range of partial to complete
inhibition of their respective targets (50, 114, 115). Aliskiren was provided by Novartis.
Enalapril (Cat# E6888) and losartan (Cat# 61188) were purchased from Sigma-Aldrich
(St. Louis, MO, USA).

24

Antisense oligonucleotide administration
All antisense oligonucleotides were provided by ISIS Pharmaceuticals (Carlsbad, CA).
Two AGT ASOs with different targeting sequences, ISIS #261333 (5´
TCTTCCACCCTGTCACAGCC 3´) and ISIS #487022 (5´ TCATCATTTATTCTCGGTCA
3´), are 20-mer phosphorothioate oligonucleotides perfectly complementary to mouse
AGT mRNA. They were composed of three 2´-O-methoxyethyl-modified ribonucleosides
at the 3´ and 5´ ends with 2´-deoxynucleosides in between. A control ASO, ISIS #
141923 (5´ CCTTCCCTGAAGGTTCCTCC 3´) was designed not to target any transcript,
including AGT. Animals were injected intraperitoneally with either control ASO or AGT
ASO diluted in PBS at different doses (12.5, 25 and 50 mg/kg/day), once a week until
termination.

Irradiation and bone marrow repopulation
This procedure was performed as described previously (116). Bone marrow was
harvested from Agt-/- (B6.129P2.Agt tm1Unc/J; stock # 002681, The Jackson laboratory )
or Agt+/+ mice and injected (1 x 107 cells/mouse) into age-matched male Ldlr-/- recipient
mice that had been lethally irradiated. Four weeks after bone marrow repopulation,
recipient mice were placed on western diet for the next 12 weeks.

Quantification of atherosclerosis
Atherosclerosis was quantified on the intima of the ascending region, aortic arch and 3
mm of the descending region using an en face method with ImagePro software as
described previously (117, 118).

Body composition
Body composition was measured on conscious mice in a constrained tube using
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EchoMRI-100™ (Echo Medical Systems, Houston, TX) that reads whole body fat mass,
lean mass, and water content within 2 minutes.

Systolic blood pressure measurements
Systolic blood pressure was measured on conscious mice using a non-invasive tail-cuff
system (Kent Scientific Corporation, Torrington, CT, USA) following a standardized
protocol described previously (119).

Intestinal fat absorption
We use sucrose polybehenate (SPB) as a marker for noninvasive measurement of
intestinal fat absorption. SPB is part of olestra (Olean; P&G, Cincinnati, OH), a
commercially used long-chain fatty acid ester blend. Although virtually identical to
triglycerides in physical properties (120), olestra is not hydrolyzed by pancreatic lipase
and not absorbed through the intestine (121). In addition, olestra does not interfere with
normal dietary triglycerides absorption (122). As described previously (123), mice were
individually caged and fed test diet containing 5% SPB for 2 or 3 days. A few fecal
pellets were collected for each mouse, and approximately 10 mg (a single fecal pellet)
were assayed. Intestinal fat absorption was calculated from the ratios of behenic acid to
other fatty acids in diet and feces as analyzed by gas chromatography of fatty acid
methyl esters.

Metabolic cages
Metabolic parameters were measured by indirect calorimetry with a TSE Labmaster
Platform (TSE System). Mice were individually placed in metabolic chambers and
measured for 5 days after 2 days of acclimation. Mice were fed the same western diet in
the chambers as in their home cages.
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Metabolome analysis
Unbiased global metabolite profiling were conducted in liver and serum, comparing
between hypoAGT mice and wild type controls, under contract with Metabolon,
Inc.(Durham, NC). A total of 12 liver and 18 serum samples were extracted and
prepared for analysis using a proprietary series of organic and aqueous extractions to
remove the protein fraction while allowing maximum recovery of small molecules. The
extracted samples were split into equal parts for analysis on the GC/MS and LC/MS/MS
platforms. Also included were several technical replicate samples created from a
homogeneous pool containing a small amount of all study samples. Recovery standards
were added prior to the first step in the extraction process for QC purposes.

Compounds were identified by comparison to library entries of purified standards or
recurrent unknown entities. Identification of known chemical entities was based on
comparison to metabolomic library entries of purified standards. As of this writing, more
than 1000 commercially available purified standard compounds had been acquired
registered into LIMS for distribution to both the LC and GC platforms for determination of
their analytical characteristics. The combination of chromatographic properties and mass
spectra gave an indication of a match to the specific compound or an isobaric
entity. Additional entities could be identified by virtue of their recurrent nature (both
chromatographic and mass spectral). These compounds have the potential to be
identified by future acquisition of a matching purified standard or by classical structural
analysis.

For this experiment, two types of statistical analysis were performed, significance tests
and classification analysis. For pair-wise comparisons, Welch’s t-tests and/or Wilcoxon’s
rank sum tests was performed. For other statistical designs, various ANOVA procedures
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(e.g., repeated measures ANOVA) were performed. For classification, random forest
analyses were used. Random forests give an estimate of how well individuals in a new
data set are classified into each group, in contrast to a t-test, which tests whether the
unknown means for two populations are different or not. Random forests create a set of
classification trees based on continual sampling of the experimental units and
compounds. Then each observation is classified based on the majority votes from all the
classification trees. Statistical analyses are performed with the program “R”.

Microarray analysis
Global differential gene expression induced by hepatic AGT deficiency was determined
in liver, white adipose tissue (epidydymal fat), and brown adipose tissue using Affymetrix
GeneChip Mouse Gene 2.0 ST. Total RNA (100 ng) for each sample was extracted
using RNeasy Mini Kit (Qiagen). RNA integrity, measured by 28S/18S ratio, was
determined with Bioanalyzer 2100 (Agilent). Microarray hybridization was performed in
London Regional Genomics Centre (London, ON, Canada). Data were analyzed with
Partek Genomics Suite (Partek Incorporated; St. Louis, MO).

Statistical analysis
Data are represented as means ± standard error of means. SigmaPlot version 12.0
(SYSTAT Software Inc., Chicago, IL) was used for statistical analyses. To compare
continuous response variables between two groups, an unpaired two-tailed Student’s t
test was used for normally distributed variables and Mann-Whitney U test was performed
for non-normally distributed variables. To compare more than two groups of a study, we
used one-way ANOVA for normally distributed variables and Kruskal-Wallis one way
ANOVA on Ranks for non-normally distributed variables, respectively. P < 0.05 was
considered statistically significant.
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Results

Mice with global AGT reduction were protected from atherosclerosis
To examine the role of AGT in atherosclerosis, we started to generate Agt/Ldlr double
knockout mice. Global AGT deficient mice were generated nearly two decades ago (65,
66). However, these mice are not suitable for our study because of their poor neonatal
survival rate and severe developmental problems. To develop tissue-specific AGT
deficient mice, we floxed exon 2 of the mouse AGT gene with a neo cassette
immediately after exon 2 as described previously (34) (Figure 2.1). These AGT floxed
mice were then crossed with Ldlr−/− mice. Unexpectedly, the resulting mice had greatly
reduced AGT mRNA abundance in all examined tissues, including liver, kidney, adipose
tissue, and brain (Figure 2.2). We designated them as hypomorphic AGT (hypoAGT)
mice. Unlike global AGT deficient mice, hypoAGT mice had normal neonatal survival
rates, and were grossly healthy with a normal life span. With suppressed AGT mRNA
expression, hypoAGT mice have barely detectable plasma AGT (Figure 2.3) and lower
systolic BP (Figure 2.4).

To assess the effects of AGT global reduction on atherosclerosis, 8-10 week old
hypoAGT mice and their wild type controls were fed a western diet (0.2% cholesterol,
42% calories from fat) to induce hypercholesterolemia. Plasma AGT concentrations
remained unchanged in both groups fed the western diet (Figure 2.3). After 12 weeks, all
mice developed severe hypercholesterolemia, although plasma total cholesterol
concentrations were slightly lower in hypoAGT mice (Figure 2.5). HypoAGT mice
developed minimal atherosclerotic lesions with only 1.9% intimal area in the arch
covered by lesions, while wild type controls showed a nearly 9-fold increase at 17.4%
(Figure 2.6).
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AGT deficiency in hepatocytes was responsible for protection against
atherosclerosis
Given that global AGT reduction protects against atherosclerosis, we sought to examine
whether circulating or local (lesion) AGT contributes to these effects. On the basis of the
critical roles of macrophage RAS in atherosclerosis (50, 115, 124), we performed a bone
marrow transplantation study, in which recipient Ldlr-/- mice were irradiated and
replenished with bone marrow cells from either Agt-/- or Agt+/+ donor mice. These
chimeric mice were placed on western diet for 12 weeks. We found that the AGT
genotype of donors had no effects on atherosclerosis in recipients (Figure 2.7),
suggesting AGT deficiency in cells of hematopoietic linage does not decrease
atherosclerosis.

As hepatocytes are the source for circulating AGT (36), we determined whether
hepatocyte-specific deletion of AGT would recapitulate the phenotypes in hypoAGT
mice. After removal of the neo cassette, AGT floxed mice (with normal plasma AGT) in
LDL receptor -/- background were bred to albumin promoter-driven Cre transgenic mice
to generate hepatocyte-specific AGT deficient mice, designated as hepAGT-/- mice
(Figure 2.8). We confirmed that AGT deficiency was specific to liver in hepAGT-/- mice
by examining AGT mRNA abundance in major AGT expressing tissues, including liver,
adipose tissue, kidney, and brain (Figure 2.9). Consistent with a previous report (36),
hepatic AGT deficiency depleted plasma AGT concentrations to a similar extent as in
hypoAGT mice as well as lowering systolic BP (Figure 2.10, 2.11).
Following the same experimental procedures as hypoAGT mice, we evaluated
atherosclerosis in hepAGT-/- mice and their wild type littermates. While hepatic AGT
deficiency had no effects on plasma total cholesterol concentrations (Figure 2.12),
hepAGT-/- mice reduced atherosclerosis to a similar extent observed in hypoAGT mice
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(Figure 2.13). Together, hepatic AGT is responsible for the protection against
hypercholesterolemia-induced atherosclerosis.

AGT ASO reduced atherosclerosis
As hepatic AGT is a potential target against atherosclerosis and AGT expression is
mainly regulated at the transcriptional level, we developed antisense oligonucleotides
(ASO) to inhibit AGT. To evaluate the effect of AGT ASO on atherosclerosis, 8-10 weekold Ldlr-/- mice received either control ASO or one of the two AGT ASOs with different
targeting sequences weekly, starting 1 week prior to western diet feeding. Intraperitoneal
injection of AGT ASO efficiently reduced AGT mRNA abundance in liver as well as in
kidney and adipose tissues (Figure 2.14). Accordingly, plasma AGT concentrations
showed nearly a 90% reduction in AGT ASO administered mice compared with those
receiving control ASO (Figure 2.15). Consistent with blood pressure lowering and antiatherogenic effects of the classic RAS inhibition (56), AGT ASO administered mice had
lower systolic blood pressure and profoundly reduced atherosclerotic lesions, compared
with mice administered control ASO (Figure 2.16, 2.17). One of the AGT ASO (AGT-2)
had effects on plasma total cholesterol, thus only AGT ASO (AGT-1) was used in most
of the following study (Figure 2.18).

AGT ASO prevented diet-induced obesity
For all study mice, we measured body weight weekly to monitor their general health. We
noticed that both hypoAGT mice and hepAGT-/- mice gained less body weight compared
with their wild type controls, respectively (Figure 2.19). Based on body composition
analysis by EchoMRI, the body weight difference was attributable to diminished fat mass
gain (Figure 2.20). We were aware of previous reports that global deletion of major
components of the RAS, including AGT, ACE, renin, and AT1 receptors, resulted in
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lower body weight (92, 125, 126). In addition, all these knockout mice suffered from
severe development problems and health issues. Given that all 3 classes of inhibitory
drugs against the RAS have no effect on body weight in humans, it is reasonable to
conclude that the lean phenotypes resulted from global deficiency of the RAS
components were attributed to developmental problems and classic RAS inhibition has
minimal effect on body weight. Therefore, we were surprised that age-matched Ldlr−/−
mice administered AGT ASO had impaired body weight gain (Figure 2.21) when fed the
same western diet, which was not observed on any of the three classic modes of RAS
inhibition (Figure 2.22). AGT ASO administered mice were apparently leaner without any
health issues compared with control ASO administered mice (Figure 2.23). While lean
mass was not different between AGT ASO and control ASO administered mice, fat mass
growth was diminished in AGT ASO administered mice (Figure 2.24), which was
confirmed by measuring tissue weight of epididymal, retroperitoneal, and inguinal fat
(data not shown). Consistently, AGT ASO administered mice had much smaller
adipocytes, as shown by the H&E staining of epididymal fat (Figure 2.25).

AGT deficiency tipped energy balance by increasing energy expenditure
To investigate the changes in energy balance induced by pharmacological or genetic
AGT inhibition, we performed an intestinal fat absorption assay and indirect calorimetry
studies on AGT ASO administered mice as well as hypoAGT mice and hepAGT-/- mice.
AGT inhibition did not affect intestinal fat absorption (Figure 2.26) and food intake
(Figure 2.27), except that hypoAGT mice had increased food intake compared with their
wild type controls. AGT ASO administered or hepAGT-/- mice showed no difference in
physical activity compared with their corresponding controls (Figure 2.28). Consistent
with previous report (92), hypoAGT mice exhibited increased physical activity (Figure
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2.28). AGT inhibition led to increased oxygen consumption (Figure 2.29) and carbon
dioxide production (Figure 2.30) during both light and dark cycles.

Consistently, AGT inhibition increased uncoupling protein 1 (Ucp1) gene expression by 2
folds in brown adipose tissue (Figure 2.31A). We did not find changes in genes involved
in lipid catabolism in liver, such as carnitine palmitoyltransferase 1 (Cpt1) and hepatic
lipase (Lipc) (Figure 2.31B, C), but found downregulation in genes involved in fatty acid
synthesis and lipogenesis in liver, such as fatty acid synthase (Fasn), stearoyl-Coa
desaturase (Scd1), and peroxisome proliferator-activated receptor gamma (PPARg)
(Figure 2.31D, E and, F). Indeed, both hypoAGT mice and hepAGT-/- were protected
from liver steatosis with lower liver mass and liver triglycerides content (Figure 2.32A-E).

AGT ASO regressed diet-induced obesity
To assess whether the energy expenditure elevated by AGT ASO is sufficient to regress
established obesity, we fed 8-10 week-old Ldlr−/− mice the western diet for 12 weeks to
induce body weight gain, then randomized them into two groups receiving weekly
injection of either control or AGT ASO with continuous western diet feeding. AGT ASO
administration lowered systolic blood pressure in obese Ldlr-/- mice by 20 mmHg (Figure
2.33A). In contrast to continuous body weight gain in mice receiving control ASO, AGT
ASO administered mice stopped body weight gain 2 weeks after initial AGT ASO
injection, then started losing weight at a constant rate for 6 weeks, and maintained body
weight afterwards (Figure 2.33B). Weight loss in AGT ASO administered mice was due
to decline in fat mass, as lean mass remained the same (Figure 2.33C,D). In contrast,
following similar experimental protocol, mice infused with aliskiren, a renin inhibitor, had
lower systolic blood pressure (Figure 2.33E), but comparable body weight gain to mice
infused with PBS (Figure 2.33F).
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AGT deficiency decreased lipid metabolites in both liver and plasma
To examine global metabolic changes resulting from AGT deficiency, unbiased
biochemical profiles were determined in liver and plasma. Comparison of global
biochemical profiles revealed altered metabolism in all nutrient categories, amino acids,
carbohydrates, lipids, and nucleotides, in hypoAGT mice, compared with AGT+/+ mice.
Overall, we observed more decrease in lipid metabolites, and more increase in other
categories, in both liver and serum (Figure 2.34).

AGT deficiency resulted in broad alteration in gene expression in brown fat
To investigate AGT deficiency induced differential gene expression, we performed global
gene profiling, using whole genome gene chips, on three tissue types including liver,
white adipose tissue (epididymal fat), and brown adipose tissue, comparing hepAGT-/mice with hepAGT+/+ mice. We screened a total of 35,000 RefSeq transcripts for
differences in gene expression. For better visualization, we generated a clustered heat
map with a criterion of 1.3 folds or larger change in gene expression. Interestingly, AGT
deficiency had much more extensive impact on gene expression of brown adipose tissue
than both liver and white adipose tissue (Figure 2.35), suggesting a role of brown
adipose tissue in AGT deficiency-induced lean phenotype.
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Figure 2.1 Construct map of hypoAGT mice. The presence of the neo cassette in
intron 2 unexpectedly suppressed AGT gene expression globally, possibly by interfering
with normal RNA splicing of AGT.
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Figure 2.2 AGT mRNA abundance was dramatically reduced in hypoAGT mice. n =
2-3 per group. All data are the mean ± SEM. * p < 0.05, Student’s t test.
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Figure 2.3 Plasma AGT concentrations were dramatically lower in hypoAGT mice.
n = 7-9 per group. All data are the mean ± SEM. * p < 0.001 versus AGT+/+, two way
ANOVA.
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Figure 2.4 Systolic blood pressure was lower in hypoAGT mice. Mice were fed the
western diet. n = 16-17 per group. All data are the mean ± SEM. * p < 0.001, Student’s t
test.
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Figure 2.5 Plasma Total Cholesterol was lower in hypoAGT mice. Mice were fed the
western diet for 12 weeks. n = 16-17 per group. All data are the mean ± SEM. * p < 0.01,
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Figure 2.6 Atherosclerosis was greatly reduced in the arch of hypoAGT mice. It
was quantified as percent area covered by lesions. n = 16-17 per group. Triangles
represent individual mice, circles with error bars are the mean ± SEM. * p < 0.001,
Student’s t test.
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Figure 2.7 Atherosclerosis in arch of chimeric Ldlr-/- mice repopulated with bone
marrow cell from Agt+/+ or Agt-/- mice was not different, regardless of genotype of
donors. It was quantified as percent area covered by lesions. n = 14 per group.
Triangles represent individual mice, circles with error bars are the mean ± SEM.
Student’s t test.

Figure 2.8 Breeding strategy of hepatocyte-specific AGT deficient mice (hepAGT-/). Alb-cre0/0 x Agtf/f x Ldlr-/- females were bred with Alb-cre1/0 x Agtf/f x Ldlr-/- males to
generate hepAGT-/- and their wild type littermates hepAGT+/+.
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Figure 2.9 AGT mRNA abundance was specifically reduced in the liver of hepAGT/- mice. n = 4-7 per group. All data are the mean ± SEM. * p < 0.05, Student’s t test.
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ANOVA.
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Figure 2.11 Systolic blood pressure was lower in hepAGT-/- mice. n = 10 per group.
All data are the mean ± SEM. * p < 0.01, Student’s t test.
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Figure 2.12 Plasma total cholesterol was not different in hepAGT-/- and
hepAGT+/+ mice. Mice were fed the western diet for 12 weeks. n = 6-7 per group. All
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Figure 2.13 Atherosclerosis was greatly reduced in the arch of hepAGT-/- mice. It
was quantified as percent area covered by lesions. n = 16-18 per group. Triangles
represent individual mice, circles with error bars are the mean ± SEM. * p < 0.001,
Student’s t test.
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Figure 2.14 AGT mRNA abundance was greatly reduced in mice administered AGT
ASO. Mice were administered control ASO (CON), AGT ASO #261333 (AGT-1), or AGT
ASO #487022 (AGT-2), at a dose of 50 mg/kg. n = 5-6 per group. All data are the mean
± SEM. * p < 0.01 versus CON,# p < 0.05 versus AGT-1, one way ANOVA.
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Figure 2.15 Plasma AGT concentrations were greatly reduced in Ldlr-/- mice 9
weeks post initial AGT ASO injection. Mice were administered control ASO (CON),
AGT ASO #261333 (AGT-1), or AGT ASO #487022 (AGT-2), at a dose of 50 mg/kg. n =
10 per group. All data are the mean ± SEM. * p < 0.001 versus CON, one way ANOVA.
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Figure 2.16 Systolic BP was lowered in Ldlr-/- mice 4 weeks post initial AGT ASO
injection. Mice were administered control ASO (CON), AGT ASO #261333 (AGT-1), or
AGT ASO #487022 (AGT-2), at a dose of 50 mg/kg. n = 10 per group. All data are the
mean ± SEM. * p < 0.01 versus CON, one way ANOVA.
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Figure 2.17 Atherosclerosis was greatly reduced in the arch of Ldlr-/- mice
administered AGT ASO. It was quantified as percent area covered by lesions. Mice
were administered control ASO (CON), AGT ASO #261333 (AGT-1), or AGT ASO
#487022 (AGT-2), at a dose of 50 mg/kg. n = 9-10 per group. Triangles represent
individual mice, circles with error bars are the mean ± SEM. * p < 0.01 versus CON, one
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Figure 2.18 Plasma total cholesterol in Ldlr-/- mice fed the western diet for 12
weeks. Mice were administered control ASO (CON), AGT ASO #261333 (AGT-1), or
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AGT ASO #487022 (AGT-2), at a dose of 50 mg/kg. n = 10 per group. All data are the
mean ± SEM. * p < 0.05 versus CON, one way ANOVA.
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Figure 2.19 Diet-induced weight gain was suppressed in hypoAGT and hepAGT-/mice. Mice were fed the western diet for 12 weeks. n = 10-12 per group. All data are the
mean ± SEM. P < 0.001 between groups, two way repeated measures ANOVA.
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Figure 2.20 Fat mass, not lean mass, was suppressed in hypoAGT and hepAGT-/mice. Body composition is determined by EchoMRI at week 0 (baseline) and week 12 of
the western diet feeding. n = 10-12 per group. All data are the mean ± SEM. * p < 0.01
versus wild type control, two way ANOVA.
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Figure 2.21 Diet-induced weight gain was suppressed in mice administered AGT
ASO. Mice were administered control ASO (CON), AGT ASO #261333 (AGT-1), or AGT
ASO #487022 (AGT-2), at a dose of 50 mg/kg. ASOs were injected initially one week
prior to 12 weeks of the western diet feeding, and once a week until termination. n = 10
per group. All data are the mean ± SEM. p < 0.001 between CON ASO and either of
AGT ASO group, two way repeated measures ANOVA.
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Figure 2.22 Diet-induced body weight gain was not affected in mice administered
Aliskiren, Enalapril, or Losartan. Mice were fed the western diet for 12 weeks. n = 10
per group. All data are the mean ± SEM.
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Figure 2.23 Representative images of Ldlr-/- mice administered CON ASO (CON) or
AGT ASO (AGT) fed the western diet for 12 weeks.
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Figure 2.24 Fat mass, not lean mass, was suppressed in mice administered AGT
ASO. Body composition was determined by EchoMRI post 12 weeks of the western diet
feeding. Mice were administered control ASO (CON), AGT ASO #261333 (AGT-1), or
AGT ASO #487022 (AGT-2), n = 10 per group. All data are the mean ± SEM. * p < 0.01
versus CON, one way ANOVA.
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Figure 2.25 H&E staining of epididymal fat from mice administered control ASO
(CON) or AGT ASO (AGT).
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Figure 2.26 Intestinal fat absorption was not affected in hypoAGT, hepAGT-/-, or
AGT ASO administered mice. Mice were fed diet supplemented with 5% sucrose
polybehenate. n = 6 per group. All data are the mean ± SEM. Student’s t test.
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Figure 2.27 Food intake was higher in hypoAGT mice, but not different in hepAGT/- and AGT ASO administered mice, compared with their wild type controls,
respectively. Mice were fed the western diet. n = 6 per group. All data are the mean ±
SEM. * p < 0.01 vs AGT+/+, Student’s t test.
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Figure 2.28 Physical activity was higher in hypoAGT mice, but not different in
hepAGT-/- and AGT ASO administered mice, compared with their wild type
controls, respectively. It was quantified as movement counts per hour. n = 6 per group.
All data are the mean ± SEM. * p < 0.01 vs AGT+/+, Student’s t test.
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Figure 2.29 O2 consumption, in a 24-h period, was higher in hypoAGT, hepAGT-/-,
and AGT ASO administered mice, compared with their wild type controls,
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respectively. Mice were fed the western diet. n = 6 per group. All data are the mean ±
SEM. p < 0.05 versus CON, Student t test.

56

A
AGT+/+
hypoAGT

4

*

4

VCO2 (l/h/kg)

VCO2 (l/h/kg)

6

2

0
0

3

6

9
12
15
Time (hours)

18

3
2
1
0

21

AGT+/+ hypoAGT

B
hepAGT+/+
hepAGT-/-

4

4

VCO2 (l/h/kg)

VCO2 (l/h/kg)

6

2

0
0

3

6

9
12
15
Time (hours)

18

*

3
2
1
0

21

hepAGT +/+

-/-

C

CON
AGT

4

VCO2 (l/h/kg)

VCO2 (l/h/kg)

6

4

2

0
0

3

6

9
12
15
Time (hours)

18

*

3
2
1
0

21

CON

AGT

Figure 2.30 CO2 production, in a 24-h period, was higher in hypoAGT, hepAGT-/-,
and AGT ASO administered mice, compared with their wild type controls,
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respectively. Mice were fed the western diet. n = 6 per group. Data were collected
every 30 minutes, represented as the mean ± SEM. p < 0.05 versus CON, Student t test.
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Figure 2.31 Gene expression profiling using qPCR in hepAGT-/- mice and
hepAGT+/+ mice fed the western diet for 12 weeks. Relative expression is
normalized to β-actin abundance. (A) Ucp1: uncoupling protein 1 in brown adipose
tissue; (B) Cpt1: carnitine palmitoyltransferase I in liver; (C) Lipc: hepatic lipase in liver;
(D) Fasn: fatty acid synthase in liver; (E) Scd1: stearoyl-Coa desaturase in liver; (F)
Pparg: peroxisome proliferator-activated receptor gamma in liver. n = 5 - 6 per group. All
data are the mean ± SEM. * p < 0.01 versus hepAGT+/+, Student’s t test. (Note: MannWhitney Rank Sum Test was used for Pparg data as it failed Equal Variance Test.)
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Figure 2.32 AGT inhibition protects against liver steatosis. Liver weight (A) and liver
triglyceride (B) of the western diet-fed hypoAGT and AGT+/+ mice; n = 6-7 per group. All
data are the mean ± SEM. * p < 0.01 versus AGT+/+, Student’s t test. (C) H&E staining
of liver of hypoAGT and AGT+/+ mice. Liver weight (D) and liver triglycerides content (E)
of the western diet-fed hepAGT-/- and hepAGT+/+ mice. n = 6-7 per group. All data are
the mean ± SEM. * p < 0.01 versus hepAGT+/+, Student’s t test.
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Figure 2.33 AGT ASO, but not aliskiren, regresses diet-induced obesity. Systolic
blood pressure (A), weekly body weight (B), lean mass (C), and fat mass (D) of mice
with established obesity adiminstrated control ASO (CON) and AGT ASO (AGT).
Systolic blood pressure (E) and weekly body weight (F) of mice with established obesity
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administered aliskiren and vechicle (PBS). n = 10 per group. All data are the mean ±
SEM. * p < 0.01 versus CON or Vechicle, Student’s t test or one way ANOVA.
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Figure 2.34 Global metabolite profiling in liver and plasma of hypoAGT mice. A
total of 311 biochemicals in liver and 336 in plasma were identified using unbiased
metabolic profiling. Metabolites, represented by colored line, are grouped into six
categories (left). The two pie charts break down the metabolites into up/down-regulated
or unchanged with p value indicated. n = 5/group for liver, n = 9/group for plasma.
Differences were determined using Welch’s Two Sample t-test. p ≤ 0.05 was taken as
significant, 0.05 < p < 0.1 identified biochemical approaching significance.
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Figure 2.35 Clustered heat map of genes with 1.3 folds or larger change in expression of hepAGT-/- mice. Red:

Table 2.1 Primers for gene expression profiling by qPCR.
Gene

Primer (Forward 5' - 3')

Primer (Reverse 5' - 3')

Product Size (bp)

Agt

CTGACCCAGTTCTTGCCAC

AACCTCTCATCGTTCCTTGG

147

Actb

GCCTTCCTTCTTGGGTATGG

GCACTGTGTTGGCATAGAGG

107

Cpt1

CGCACATTACAAGGACATGG

GAAGAGCCGAGTCATGGAAG

64

Fasn

TACCATGGCAACGTGACACT

GTCACACACCTGGGAGAGGT

93

Lipc

ACGTGGCTGCTCTTCTCCTA

AGGTGAACTTTGCTCCGAGA

64

Pparg

TTCAGAAGTGCCTTGCTGTG

CCAACAGCTTCTCCTTCTCG

84

Scd1

TATGGATATCGCCCCTACGA

GGGAAGGTGTGGTGGTAGT

105

Ucp1

TCAGGATTGGCCTCTACGAC

TGCCACACCTCCAGTCATTA

110
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Chapter Three: The Role of Cys18-Cys137 Disulfide Bridge in
Angiotensinogen

This chapter is based on the manuscript titled “The role of angiotensinogen disulfide
bridge”, submitted to Nature, with Congqing Wu as the first author. This projected is
supported by AHA Predoctoral Fellowship awarded to Congqing Wu.

Figures based on experiments conducted by others are listed here: figure 3.2, 3.3 from
Yingchuan Xu.

Synopsis

A conserved structural feature of angiotensinogen is the disulfide bridge between Cys18
and Cys138 in humans, and Cys18 and Cys137 in mice. The formation of this disulfide
bridge could trigger conformational changes in angiotensinogen, specifically the
positioning of the N-terminus, which will facilitate renin cleavage of angiotensinogen
between Leu10 and Val11 in the N-terminus. It was predicted that the redox-sensitive
disulfide bridge might change the efficiency of angiotensinogen cleavage by renin bound
to prorenin receptor to release angiotensin II, thus modulating angiotensin II-dependent
functions. To directly test this prediction in vivo, we determined effects of the presence
and absence of this disulfide bridge on angiotensin II concentrations and responses in
mice expressing either native angiotensinogen or Cys18Ser, Cys137Ser mutated
angiotensinogen in liver. Contrary to the prediction, disruption of Cys18-Cys137 disulfide
bridge in angiotensinogen had no discernible effects on angiotensin II production and
angiotensin II-dependent functions in mice.
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Introduction

As the only precursor to all angiotensin peptides, angiotensinogen (AGT) is secreted
from hepatocytes into the circulation as a mature protein of 452 amino acids (3, 107). It
is well recognized that renin is the major enzyme that cleaves off the first 10 amino acids
from the N-terminus of AGT to release angiotensin (Ang) I. AngI is subsequently cleaved
by angiotensin-converting enzyme (ACE) to form the major bioactive peptide of the
renin-angiotensin system (RAS), AngII. Cleavage of AGT by renin is the rate-limiting
step in producing AngII, implicating that the efficiency of AGT cleavage determines the
rate of AngII production, and consequently influences AngII-related physiological and
pathophysiological effects.

Since its discovery in 1939, plasma AGT has been viewed as a passive substrate
reservoir for all angiotensin peptides. No regulatory role of AGT has been tested
experimentally until its crystal structure was solved in 2010 (11). Zhou and colleagues
resolved AGT structure to 2.1 Å resolution using a recombinant non-glycosylated form of
the protein (11). It was predicted that AGT was secreted in an oxidized form containing a
disulfide bridge between Cys18 and Cys138 in humans, and Cys18 and Cys137 in mice
(3, 5, 11). It was also proposed that this disulfide bridge could constrain the N-terminus
of AGT in a manner that facilitated its cleavage by renin (10, 11). In addition, the
disulfide bridge formed in the secreted protein was labile, and its reduction by a
proposed plasma thiol-reductase system led to decreased access to the renin cleavage
site. Therefore, it was speculated that the reduced form of AGT was a less efficient
substrate for renin. The regulatory role of the disulfide bridge in AGT was supported by a
correlation of increased ratio of oxidized versus reduced forms of AGT in pregnant
women with preeclampsia compared with normotensive pregnant women. Overall, this
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model predicted that AngII-dependent responses could be regulated by the presence of
a disulfide bridge between Cys18 and Cys138.

Adeno-associated virus (AAV) is nonpathogenic, with a single-stranded DNA genome.
Its ability to infect both nondividing and dividing cells, long-term expression in vivo, and
low immunogenicity makes AAV vectors one of the most promising viral vectors for gene
therapy in humans (127). AAV2 is the first fully cloned and the most wildly used AAV
serotype. While AAV2 delivers persistent transgene expression, its expression levels are
very low (128). This has led to development of vectors derived from novel AAV
serotypes such as AAV 7, 8, and 9 (129, 130). Studies have demonstrated the
importance of the serotype-specific capsid in transduction efficiency (131-133). Hybrid
vectors like AAV2/8 (AAV2 rep gene fused with AAV8 cap gene) with tissue-specific
promoters used in this study have been shown to direct robust and stable transgene
expression in liver (130, 134).

In the present study, we investigated the functional consequences of disrupting the
disulfide bridge in AGT in blood pressure and atherosclerosis, as AngII regulates blood
pressure and promotes atherosclerosis (21, 50, 56, 83, 84, 135). We developed
hepatocyte-specific AGT deficient mice (hepAGT-/-) in which plasma AGT
concentrations were severely depleted. AAV vectors were injected to replenish, in a
hepatocyte-specific manner, either native AGT or mutated AGT (Cys18Ser, Cys137Ser)
that were unable to form the disulfide bridge.

68

Methods

Ethics statement
All animal experiments reported in this part were performed with approval of the
University of Kentucky Institutional Animal Care and Use Committee (University of
Kentucky IACUC protocol number: 2006-0009).

Mouse housing conditions and diets
All mice were maintained in individually vented cages (maximally 5 mice per cage) in a
barrier facility (14:10 hour light-dark cycles, ambient temperature of 22°C). Cage
bedding was Teklad Sani-Chip bedding (Cat # 7090A, Harlan Teklad, Madison, WI).
Mice were fed a normal rodent laboratory diet (Diet # 2918, Harlan Teklad, Madison, WI)
and provided with drinking water ad libitum from a reverse osmosis system. Two weeks
after AAV injections, all mice were fed a saturated fat-enriched diet (milk fat 21% wt/wt;
Diet # TD.88137, Harlan Teklad, Madison, WI) for 12 weeks. This diet was developed in
1988 by collaboration between Harlan Teklad and Rockefeller University to mimic the
nutrient composition of typical foods from western food chains (111). It is referred to as
western diet.

Development of hepatocyte-specific AGT deficient mice
A targeting construct with loxP sites flanking exon 2 of AGT followed by a neo cassette
was transfected into embryonic stem cells from a 129 mouse strain. After selection,
positive cells were injected into blastocysts of C57BL/6 mice. The following breeding
was maintained in a C57BL/6 background until homozygous AGT floxed mice were
obtained, as previous described (34, 112). The breeding strategy to develop mice with
hepatocyte-specific deficiency of AGT included 4 steps: (1) AGT floxed mice were bred
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to FLPe mice (B6;SJL-Tg(ACTFLPe)9205Dym/J, Stock # 003800, N2 to C57BL/6 strain,
The Jackson Laboratory, Bar Harbor, ME) to remove the neo cassette insertion in intron
2 of mouse AGT gene. (2) After removal of the neo cassette, these mice were bred to
LDL receptor-/- mice (B6.129S7-Ldlrtm1Her/J, Stock # 002207, N13 to C57BL/6 strain,
The Jackson Laboratory) to generate Agtf/f x Ldlr-/- mice. (3) Male mice expressing Cre
recombinase under the control of a hepatocyte-specific albumin promoter (B6.CgTg(Alb-cre)21Mgn/J, Stock # 003574, N7 to C57BL/6 strain, The Jackson laboratory)
were bred to female Ldlr-/- mice to generate male Alb-cre1/0 mice in the LDL receptor-/background. (4) Alb-cre0/0 x Agtf/f x Ldlr-/- females were bred with Alb-cre1/0 x Agtf/f x Ldlr-/males to generate hepatocyte-specific AGT deficient mice hepAGT-/-, and their wild type
littermates hepAGT+/+.

Production and injection of AAV vectors
AAV vectors (serotype 2/8) driven by a hepatocyte-specific thyroxine-binding globulin
(TBG) promoter were produced by the Viral Vector Core at the University of
Pennsylvania (Philadelphia, PA). These AAV vectors contained cDNA inserts encoding
mouse native AGT or AGT with mutations at Cys18 and Cys137 (the two cysteines were
replaced by two serines). AAV vector with null insertion (null AAV) was used as control.

All AAV vectors were diluted in PBS (1 x 1010 or 3 x 1010 genome copies/200 µl per
mouse) and injected intraperitoneally into study mice.

Systolic blood pressure measurements
Systolic blood pressure was measured on conscious mice using a non-invasive tail-cuff
system (Kent Scientific Corporation, Torrington, CT) following a standardized protocol
described previously (119).
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Measurement of plasma components
Blood samples were collected with EDTA (final concentration at 1.8 mg/ml) and
centrifuged at 400 g for 20 minutes, 4 °C to separate plasma. Before termination, blood
samples were collected using submandibular bleeding on conscious mice. At
termination, blood samples were collected using right ventricular puncture after
anesthesia (a mixture of ketamine 100 mg/kg and xylazine 10 mg/kg).
Plasma AGT concentrations were determined using an ELISA kit (Code # 27413,
Immuno-Biological Laboratories Co., Ltd, Takasaki-Shi, Gunma, Japan) (55).

Plasma renin concentrations were measured by quantifying AngI generated in mouse
plasma. In brief, plasma samples (8 μl) harvested with EDTA were incubated in an assay
buffer (Na2HPO4 0.1 M, EDTA 0.02 M, maleate buffer pH 6.5, phenylmethyl-sulfonyl
fluoride 2 μl; total volume of 250 μl) with an excess of rat AGT at 37 °C for 30 minutes.
Rat AGT was obtained through partial purification of nephrectomized rat plasma. This
reaction was terminated by placing samples at 100 °C for 5 minutes. AngI generated in
each sample was quantified by radioimmunoassay using a commercially available kit
(Cat # 1553; DiaSorin, Stillwater, MN).

For plasma AngII concentrations, aprotinin (0.6 TIU per 1 ml of blood; Cat # RK-APRO,
Phoenix Pharmaceuticals, Inc., CA) was added to blood samples before centrifugation.
After extraction of plasma samples using Sep-Pak C18 classic cartridges (Cat #
WAT051910; Waters Corp., Milford, MA), AngII concentrations were measured using
radioimmunoassay. The antibody used for this assay was a rabbit anti-AngII antibody
(Cat # T-4005; Bachem, Torrance, CA) as described previously (136).
Plasma total cholesterol concentrations were measured using an enzymatic kit (Cat #
439-17501; Wako Chemicals USA, Richmond, VA).
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Western blotting of oxidized versus reduced forms of mouse AGT
To determine the abundance of oxidized versus reduced form of AGT in mouse plasma,
plasma samples were incubated with methoxypolyethylene glycolmaleimide (mPEG;
Product # 63187; Sigma-Aldrich, St. Louis, MO) as described by Zhou et al (11). Briefly,
mouse plasma samples (5 μl) were incubated with mPEG (10 μl of 20 mM) in reaction
buffer (5 μl, 100 mM Tris-HCl with pH 8.0, 5 mM EDTA, and 0.15 M NaCl) at 37 °C for 3
hours. Subsequently, reducing loading buffer (Cat # 39000; Thermo Scientific, Rockford,
IL) was added to each sample, and samples were heated at 98 ˚C for 5 minutes.
Proteins (0.1 µl of plasma) were resolved by SDS-polyacrylamide gel electrophoresis,
and transferred to PVDF membranes (Cat # IPVH09120; EMD Millipore, Billerica, MA).
After blocking in fat-free milk buffer (5% wt/vol), membranes containing transferred
proteins from mouse plasma were incubated with a chicken anti-mouse AGT antibody (1
µg/ml; 1 hour at room temperature) developed by Aves Labs (Tigard, OR). The
specificity of this antibody to mouse AGT was confirmed by the absence of an
immunoreactive band in plasma of AGT deficient mice. The secondary antibody was
HRP-conjugated rabbit anti-chicken IgY (Cat # 303-035-003; Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA) incubated with membranes at a concentration of 0.5
µg/ml for 1 hour at room temperature. Immunoreactive bands were visualized by
exposing membranes on a Kodak Image Station 4000R Pro after incubation with
chemiluminescent substrate (Cat # 34080; Thermo Scientific, Rockford, IL).

Quantification of atherosclerosis
Atherosclerosis was quantified on the intima of the ascending region, aortic arch and 3
mm of the descending region using an en face method with ImagePro software as
described previously (117, 118).
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Statistical analysis
Data are represented as means ± standard error of means (SEM). SigmaPlot version
12.0 (SYSTAT Software Inc., Chicago, IL) was used for statistical analyses. To compare
multiple-group data, one way ANOVA was used for normally distributed variables and
Kruskal-Wallis one way ANOVA on Ranks was used for non-normally distributed
variables. Post-hoc analysis for these two analyses were Holm-Sidak method and
Dunn’s method, respectively, except for plasma renin concentrations in which post-hoc
analysis used Tukey-Kramer adjustment. Plasma AGT concentrations (after square root
transformation) were compared using two way repeated measures ANOVA and HolmSidak post-hoc method. P < 0.05 was considered statistically significant.

Results

AAV expression of native AGT raised plasma AGT concentrations in a dosedependent manner
To determine the optimal dosage of AAV vector that replenishes plasma AGT in
hepatocyte-specific AGT deficient mice (hepAGT-/-) mice, we evaluated two doses of
AGT AAV at 3x1010 (high dose) and 1x1010 (low dose) genome copies per mouse,
respectively. AGT AAV was constructed with insertion of native mouse AGT gene. AAV
with null insertion was included as control. AAV transgene expression was driven by
hepatocyte-specific thyroxine-binding globulin (TBG) promoter.

While hepAGT+/+ mice were infected with no AAV (PBS injection) or null AAV, hepAGT
-/- mice were infected with low dose or high dose of AGT AAV, or null AAV, by
intraperitoneal injection. Plasma samples were collected through submandibular
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bleeding on week 2, 4, 8, and 16 after AAV injection. Plasma AGT concentrations in
hepAGT-/- mice receiving AGT AAV were elevated in a dose-dependent manner, and
peaked between weeks 2 and 4, then declined modestly afterwards (Figure 3.1).
HepAGT-/- mice receiving high dose of AGT AAV vectors had plasma AGT
concentrations comparable to that of hepAGT+/+ mice during the 16 weeks post AAV
injection (Figure 3.1). On the basis of this observation, we administered AAV vectors at
3x1010 genome copies per mouse in the following studies.

AAV expression of native or mutated (C18S, C137S) AGT restored plasma AGT
concentrations
To investigate functional consequences of disrupting the C18-C137 disulfide bridge, we
compared native AGT and mutated (C18S, C137S) AGT in hepAGT-/- mice via AAV
expression of native or mutated (C18S, C137S) AGT. To achieve this, hepAGT-/- mice
were infected with null AAV, native AGT AAV, or mutated (C18S, C137S) AGT AAV. As
a control, hepAGT+/+ mice were infected with null AAV.

To evaluate expression efficiency and stability of AAV vectors, we measured plasma
AGT concentrations prior to AAV injection and 2, 6, 10, and 14 weeks after AAV
injection. At baseline, all hepAGT-/- mice lacking AGT expression in hepatocytes had
barely detectable plasma AGT concentrations. The low plasma AGT concentrations
remained unchanged in hepAGT-/- mice receiving AAV vector containing the null insert
(Figure 3.2). Plasma AGT concentrations in hepAGT-/- mice receiving AAV vector
expressing either wild-type or mutated AGT peaked 2 weeks post-injection and
remained at concentrations comparable to hepAGT+/+ littermates from 6 to 14 weeks
after AAV injections. There was no difference in plasma AGT concentrations among all
groups at later intervals except for hepAGT-/- administered AAV vector containing a null
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insert (Figure 3.2).

Predominance of oxidized AGT in mouse plasma
To determine the ratio of oxidized AGT versus reduced AGT in mouse plasma, we
developed western blotting using in-house chicken antibody against mouse AGT.
Antibody specificity was demonstrated by a single distinctive band with molecular weight
of ~50 kDa in hepAGT+/+ mouse plasma and absence of a discernible band in hepAGT/- mouse plasma (Figure 3.3A). Incubation of plasma with methoxypoly-ethylene glycol
maleimide (mPEG) increased the molecular weight of AGT from hepAGT+/+ mouse
plasma by 10 kDa (Figure 3.3A). This was consistent with mPEG interacting with the two
cysteines at positions 300 and 316 on the non-renin interacting face, but being unable to
interact with two cysteines at position 18 and 137 due to disulfide linkage. These findings
demonstrated that oxidized AGT was predominant in mouse plasma.

To profile oxidized AGT and reduced AGT in mouse plasma replenished by AAV
vectors, two weeks post AAV injection, plasma was collected from all groups and
incubated with mPEG prior to Western blotting. A single band of AGT was detected in
hepAGT+/+ mouse plasma that was shifted 10 kDa from native AGT. Western blotting of
plasma AGT failed to detect any immunoreactive band in hepAGT-/- mice administered
AAV containing a null insert. In contrast, a 60 kDa immunoreactive band was clearly
detected in each mouse repopulated with native AGT, demonstrating that AAV derived
wild-type AGT was completely oxidized (Figure 3.3B). As expected, plasma in mice
replenished with mutated (C18S, C137S) AGT showed a 60 kDa band due to interaction
of mPEG with the remaining 2 cysteine residues, position 300 and 316 (Figure 3.3B).
Overall, these data demonstrated that the experimental design enabled comparisons of
AGT in forms that were either completely disulfide bridged or completely lacking the
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disulfide bridge.

Replenishment of native versus mutated AGT had equivalent effects on plasma
renin and AngII concentrations
Plasma renin concentrations were significantly increased (Figure 3.4) in hepAGT-/- mice
receiving null AAV vector due to diminished negative feedback (137), imposed by low
plasma AngII concentrations (Figure 3.5), compared with hepAGT+/+ mice receiving null
AAV vector (Figure 3.4). HepAGT-/- mice replenished with native AGT showed no
differences in plasma renin and AngII concentrations from hepAGT+/+ littermates.
However, in contrast to the prediction of structural modeling (11), plasma renin and AngII
concentrations in hepAGT-/- mice administered mutated AGT AAV were not significantly
different from those in hepAGT -/- mice administered AAV expressing native AGT
(Figure 3.4,3.5).

Replenishment of native versus mutated AGT had equivalent effects on systolic
blood pressure and atherosclerosis
Consistent with low plasma AngII concentrations in hepAGT-/- mice, administration of
AAV containing a null vector did not change the low systolic blood pressure in hepAGT-/mice (Figure 3.6). Administration of AAV vectors containing either native or mutated
AGT increased systolic blood pressure in hepAGT-/- mice to levels indistinguishable
from hepAGT+/+ littermates. However, systolic blood pressure was not significantly
different between mice expressing native and mutated AGT (Figure 3.6).

LDL receptor-/- mice develop profound hypercholesterolemia-induced atherosclerotic
lesions in the aortic arch region after 12 weeks of western diet feeding (50, 56, 115). In
this study, mice in these 4 groups all developed hypercholesterolemia (Figure 3.7).
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HepAGT-/- mice administered null AAV had significantly smaller lesions, compared with
hepAGT+/+ littermates, as measured by percent lesion area in the aortic arch region. In
contrast, hepAGT-/- mice receiving either native or mutated AGT developed pronounced
atherosclerotic lesions, and the percent lesion areas were not different between these
two groups, as well as compared with hepAGT+/+ mice (Figure 3.8).
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Figure 3.1 Plasma AGT concentrations were restored by AAV-mediated AGT
expression at a dose-dependent manner. It was measured using an ELISA kit at week
0, 2, 4, 8, and 16 weeks after AAV injection. No, no AAV; Nu, null AAV; Lo, low dose of
AGT AAV; Hi, high dose of AGT AAV. WT, hepAGT+/+; KO, hepAGT-/-. n = 4-6. Two
way repeated measures ANOVA.
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Figure 3.2 Plasma AGT concentrations were not different between hepAGT+/+ and
hepAGT-/- receiving either WT AGT or C18-137 AGT AAV. It was measured using an
ELISA kit at week 0, 2, 4, 8, and 16 weeks after AAV injection. n = 4-6. * p < 0.001
versus the other 3 groups at each time point. Two way repeated measures ANOVA.
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A

B

Figure 3.3 Only oxidized AGT was detected in mouse plasma. Oxidized AGT, at
baseline (A) and 2 weeks post AAV injection (B), was detected by Western blotting. The
AGT band showed a shift by 10 kDa due to addition of mPEG at two cysteins (position
18 and 137). Native represents mice receiving native AGT AAV; mutated represents
mice receiving C18S, C137S mutated AGT AAV; null represents mice receiving null
AAV; no represents mice receiving PBS.
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Figure 3.4 Plasma renin concentrations were not different between hepAGT-/receiving native or C18-137S AGT AAV. It was measured at termination. n = 8-11. * p
< 0.001 versus the other 3 groups, one way ANOVA. Null represents mice receiving null
AAV; native represents mice receiving native AGT AAV; C18S, C137S represents mice
receiving C18S, C137S mutated AGT AAV.
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Figure 3.5 Plasma AngII concentrations were not different between hepAGT-/receiving native or C18-137S AGT AAV. n = 8-11. * p = 0.002 versus the other 3
groups, one way ANOVA. Null represents mice receiving null AAV; native represents
mice receiving native AGT AAV; C18S, C137S represents mice receiving C18S, C137S
mutated AGT AAV.
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Figure 3.6 Systolic blood pressure was not different between hepAGT-/- receiving
native or C18-137S AGT AAV. It was measured using a non-invasive tail-cuff system 8
weeks after AAV injection. n = 4-6. * p < 0.01 versus the other 3 groups, one way
ANOVA. Null represents mice receiving null AAV; native represents mice receiving
native AGT AAV; C18S, C137S represents mice receiving C18S, C137S mutated AGT
AAV.
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Figure 3.7 Plasma cholesterol concentrations were not different between hepAGT/- receiving native or C18-137S AGT AAV. It was measured at termination. n = 8-11.
Triangles represent values of individual mice, circles represent means, and error bars
are SEM. Null represents mice receiving null AAV; native represents mice receiving
native AGT AAV; C18S, C137S represents mice receiving C18S, C137S mutated AGT
AAV.
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Figure 3.8 Atherosclerotic lesion areas were not different between hepAGT-/receiving native or C18-137S AGT AAV. It was measured on the intimal surface of the
aortic arch region using an en face method. Triangles represent values of individual
mice, circles represent means, and error bars are SEM. n = 8-11. * p < 0.001 versus the
other 3 groups, one way ANOVA. Null represents mice receiving null AAV; native
represents mice receiving native AGT AAV; C18S, C137S represents mice receiving
C18S, C137S mutated AGT AAV.
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Chapter Four: General Discussion

All experiments in the dissertation were designed to address the specific aims stated in
Chapter One: Aim 1, to investigate the role of angiotensinogen (AGT) inhibition in
atherosclerosis and obesity; Aim 2, to determine the contributes of systemic and local
AGT to atherosclerosis and obesity; Aim 3, to analyze the structure-function relationship
of Cys18-C138 linkage in AGT.

In Chapter Two, we developed two mouse models with genetic AGT inhibition, hypoAGT
mice with global AGT reduction and hepAGT -/- mice with hepatocyte-specific AGT
deficiency. We also used antisense oligonucleotides (ASO) for pharmacological AGT
inhibition. With these unique reagents, we demonstrated that whole body reduction of
AGT (hypoAGT mice) virtually ablated hypercholesterolemia-induced atherosclerosis. To
investigate the relative contributions of systemic versus local AGT to atherosclerosis, we
performed bone marrow transplantation study and found minimal contributions of local
AGT (leukocyte-derived), as the genotype of AGT in bone marrow donors had no effect
on atherosclerosis in recipient Ldlr-/- mice. Using hepAGT-/- mice, we revealed that
hepatic AGT deficiency is responsible for the protection against atherosclerosis as
hepAGT-/- mice recapitulated the anti-atherosclerotic phenotypes in hypoAGT mice. As
we routinely monitor the health of study mice by measuring body weight weekly, we
observed AGT deficiency-induced resistance to diet-induced obesity in both hypoAGT
mice and hepAGT-/- mice. We concluded Chapter Two by demonstrating that AGT ASO
in adult Ldlr-/- mice prevents and regresses diet-induced obesity.

In Chapter Three, we developed an in vivo system to examine the structure-function
relation in AGT, specifically the role of the Cys18-Cys137 disulfide bridge of mouse
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AGT, in AngII release and AngII-dependent pathophysiological effects. To achieve this,
we engineered AGT with disrupted disulfide bridge by two cysteine substitutions with
serine at position 18 and 137, respectively. Then, C18S, C137S mutated AGT was
delivered by an AAV vector to repopulate plasma AGT in hepAGT-/- mice. Essentially,
we have an in vivo system in which plasma native AGT is replaced with mutated AGT.
We demonstrated that mutated AGT lacking the disulfide bridge was equal to native
AGT in releasing Ang II, normalizing blood pressure, and contributing to atherosclerosis.
Apparently, our findings do not support the redox-sensitive disulfide bridge as a major
regulatory mechanism of AGT cleavage by renin in vivo.

The role of angiotensinogen in atherosclerosis
Atherosclerosis is a chronic inflammatory disease that progresses through many
complex biochemical and cellular events (81). There is a large body of evidence of
abnormal cholesterol metabolism being a major determinant of lesion development. This
is the main reason we bred all our study mice with LDL receptor deficient background,
as LDL receptor is a major player in cholesterol metabolism and Ldlr-/- mice have been
widely used for atherosclerosis study. Our laboratory has demonstrated that
hypercholesterolemia could exacerbate AngII-induced pathology such as abdominal
aortic aneurysms. We did not find hypercholesterolemia changes plasma AGT
concentrations. However, it is not clear whether hypercholesterolemia could change the
ratio of intact AGT versus its cleaved form, des(AngI)-AGT.

Recently, substantial data from our laboratory and other groups has demonstrated a
profound role of the RAS in experimental atherosclerosis (50, 84-86, 138). Although
being an essential regulator of blood pressure and fluid homeostasis, the RAS promotes
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atherosclerosis through neither of these effects (139, 140). In fact, as the major effector
peptide of the RAS, AngII plays critical roles in many mechanisms of atherosclerosis,
such as promoting adhesion molecules expression in endothelial cells, inducing
oxidative stress in the intima, and promoting smooth muscle cell migration. In the classic
RAS cascade, AGT is cleaved sequentially by renin and ACE to generate AngII, which
functions mainly through AT1 receptors. However, there is accumulated evidence that
other bioactive angiotensin peptides such as Ang1-7 generated through recently
discovered RAS enzyme, ACE2, could antagonize AngII (141, 142). Despite the
increasing complexity of the RAS, AGT remains the only substrate of this hormonal
system, which makes AGT an ideal target to inhibit the RAS cascade as AGT inhibition
could avoid the RAS complexity. As expected, we demonstrated that AGT inhibition,
genetically or pharmacologically, virtually ablated atherosclerosis.
More clinically relevant, we demonstrated that weekly administration of AGT ASO was
sufficient to prevent atherosclerosis in mice fed the western diet. Our pilot studies
demonstrated that AGT ASO modestly prevented the progression of preexisting
atherosclerosis, but failed to regress the pathology (data not shown). We need to
explore further on the progression mechanism as the molecular and cellular events lead
to initiation and progression would be divergent enough to require different therapeutics.

The role of AGT in obesity
Our consistent findings using multiple approaches confirmed that AGT inhibition not only
prevented atherosclerosis, but also protected against diet-induced obesity. The antiobesity features of AGT are unique because we did not observe body weight reductions
with the 3 classic modes of RAS inhibitors. In an unbiased survey of literature on
PubMed, we found a total of 83 original articles on pharmacological RAS inhibition in

88

mice with body weight data. Only 14 of them reported the effects of RAS inhibition on
body weight gain. However, effects were either minimal, waxed and waned during the
study, or accompanied by significant impact on food intake (143-156). The rest majority
of published articles did not find any effects of the 3 classic modes of the RAS inhibition
on body weight gain, which was consistent with our findings that these 3 modes showed
dose-dependent effects on atherosclerosis, but none of them had significant impact on
diet-induced body weight gain. Also, we are not aware of any literature evidence that
suggests a link between the classic RAS inhibition and body weight loss in humans.

It has drawn our attention that global deletion of AGT, renin, or ACE resulted in lower
body weight, compared with their wild type controls, respectively (92, 125, 126).
However, interpretation of the lean phenotypes could be greatly confounded by their
unhealthy conditions, as all these global knockout mouse models have low neonatal
survival rate and severe kidney developmental and growth problems due to the critical
role of the RAS in the fetal development (70, 71, 157, 158). The mechanisms underlying
these lean phenotypes are divergent: it is the combination of decreased lipogenesis in
white adipose tissue and increased locomotor activity for AGT (92), gastrointestinal loss
of fat for renin (125), and increased metabolism in the liver for ACE (126). It is
reasonable to think RAS inhibition should impact body weight gain through similar
mechanisms regardless of the target. In contrast, pharmacological and genetic
approaches used in our study overcame these developmental issues. On the basis of
these consistent phenotypic data generated from multiple mouse models to manipulate
AGT, we conclude that resistance to diet-induced obesity is specific to AGT inhibition,
which is not related to development impairment as shown in AGT, renin, or ACE
knockout mice. An intriguing question remains whether these effects of AGT inhibition
are RAS-independent. In a pilot study, we used AAV vectors to deliver des(AngI)-AGT or
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renin-resistant AGT into hepAGT-/- mice by AAV. We found that renin-resistant AGT, but
not des(AngI)-AGT, rescued the lean phenotype in hepAGT-/- mice (data not shown).
We are validating whether renin-resistant AGT is truly resistant to renin cleavage.

Lean phenotypes in AGT inhibition were not attributed to decreased caloric intake or
intestinal fat absorption, but increased energy expenditure as uniformly shown by high
oxygen consumption and carbon dioxide production. The question is which tissues are
responsible for the increased energy expenditure. Global metabolite profiling revealed
AGT inhibition decreased lipid metabolites in liver. Combined with unchanged gene
expression in lipid catabolism, it is unlikely that increased energy expenditure occurs in
liver. Global gene profiling showed that hepatocyte-specific deficiency of AGT had most
extensive impact on gene expression in brown adipose tissue, compared with liver and
white adipose tissue. Together with AGT deficiency-induced up-regulation of Ucp1 gene
expression in brown adipose tissues, this points to brown adipose tissue as the
candidates responsible for the lean phenotype. Increased metabolism in brown adipose
tissue could easily explain the fact that AGT ASO not only prevented, but also regressed
obesity, while the common mechanism for obesity prevention such as inhibiting
adipogenesis could not explain obesity regression.

Adipose tissue is best known for fat storage, as seen in white adipose tissue. It can also
use energy for heat production through specialized adipocyte, in brown adipose tissue.
Abundant UCP1 in mitochondria is the hallmark of brown adipocytes, responsible for
metabolism of thermogenesis instead of ATP synthesis. The capacity of brown adipocyte
to counteract metabolic diseases, including obesity and type 2 diabetes has drawn
intense interest (159). In humans, it was accepted for a long time that adults have too
little brown fat to impact body weight (159). However, progress in imaging revealed
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substantial presence of UCP1 positive adipocytes in adults. In addition, obese subjects
had lower mass and activity in those adipocytes (160-162). Therefore, brown adipose
tissue is of great therapeutic potential against obesity. Inhibition of AGT by ASO
regressed established obesity in mice fed the western diet, possibly by promoting brown
adipocyte activity.

Systemic AGT versus local AGT
The principal sources for AGT, renin, and ACE are liver, kidneys, and lungs,
respectively. They are considered systemic. In the past decades, there is a growing
appreciation of tissue (local) RAS in many physiological functions. Classical components
of the RAS are present in atherosclerotic lesions (50, 85, 115, 163-167). Our laboratory
has reported that macrophage derived renin or ACE promotes atherosclerosis (50, 115),
suggesting a role of local RAS in atherosclerosis. Our bone marrow transplantation
study clearly demonstrated that macrophage AGT had no effect on atherosclerosis.
However, it does not necessarily contradict our previous report on the importance of
local RAS (50, 115), as hepatocyte-derived AGT is secreted into circulation and readily
taken up by tissues to generate AngII locally. Recently, hepatocyte-derived AGT has
been showed to be the primary source of renal AngII (36). Similarly, we found
hepatocyte-specific AGT deficiency was responsible for atherosclerosis prevention.
Given that many RAS inhibitory drugs are more efficient when they can inhibit tissue
RAS, we think it is appealing that pharmacological inhibition of AGT could inhibit both
systemic and tissue RAS.

Besides hepatocytes, AGT is present in many other cell types. Adipocytes are an
abundant source for AGT (34, 168). It is possible the low but detectable plasma AGT
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concentrations in hepAGT -/- mice was due to presence of AGT in adipocytes (34).
However, adipocyte-specific AGT deficiency did not affect diet-induced obesity (34).
AGT is also expressed in kidneys. However, a recent study demonstrated that AGT
derived from liver, rather than kidneys, is responsible for normal renal function as the
primary source of renal AngII (36). We have detected AGT in macrophages (50), and
macrophage infiltration plays important role in both atherosclerosis and obesity.
However, our data excluded macrophage AGT as a possible contributor to either
atherosclerosis or body weight gain. Therefore, hepatic AGT, not tissue AGT, is the
substrate for local RAS in atherosclerosis and obesity.

The role of Cys18-Cys137 disulfide bridge
The elegant work by Zhou and colleagues (11) has provided the crystal structure of
AGT. From this structure, a novel proposal was formulated that disulfide bridge between
Cys18 and Cys138 in human AGT could regulate AngI release at a pericellular level to
modulate blood pressure. It was used in the interpretation that an 8% difference in the
percentage of oxidized AGT in plasma (synonymous with increased percentage of
disulfide bridging in AGT) was the basis for increased blood pressure in women with
preeclampsia (11). Despite being provocative, it did not establish a causal relationship
between the increase of disulfide bridging and the rise of blood pressure. Given the vast
impact of blood pressure regulation by the RAS to public health, there is a need to
validate the functional significance of the disulfide bridging in AGT.

In an in vivo system that was developed to determine structure-function relationship for
AGT, we demonstrated that mutated AGT lacking the disulfide bridge was not different
from exclusively disulfide bridged AGT in generating Ang II, recovering blood pressure,
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and contributing to atherosclerosis. Although redox status of AGT may influence the
interaction at the precision that can be obtained in vitro, our findings do not support the
redox-sensitive disulfide bridge as a major regulatory mechanism of AGT cleavage by
renin in vivo.

A critical question remains whether mouse is a valid model to test this disulfide bridge
theory based on in vitro data from human AGT. I break down my answer to the question
into three parts:

First, I discuss the structural similarity in AGT between humans and mice. In their
structural analysis, Zhou and colleagues included recombinant AGT from mouse, rat,
and human. The crystal structures of mouse AGT, solved to highest resolution at 2.1 Å,
showed that AGT cleavage site was inaccessibly buried in its N-terminal tail. The
general features of mouse AGT are preserved in the 3.15 Å rat and 3.3 Å human
structure. Moreover, human AGT contains four cysteines, but those forming the Cys18Cys138 linkage are the only two conserved in all species. Therefore, the focus of both
the study of Zhou et al (11) and that of our own study, is on a conserved structure
present in both human and mouse AGT.

Second, human plasma but not mouse plasma contains equilibrated oxidized and
reduced AGT, as oxidized AGT can be reduced by interaction with proposed thiolreductant systems in human plasma (11). Does that make our mouse studies irrelevant
to the disulfide bridge theory? This theory, arising largely from structural analysis of AGT
supported solely by in vitro analysis of the renin-AGT reaction, is based on two
assumptions: 1. The presence of the C18-C138 disulfide bridge of AGT facilitates AngI
release; 2. The ratio of reduced-to-oxidized (i.e. absence versus presence of disulfide
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bridge) AGT can be regulated to change blood pressure under certain conditions, such
as preeclampsia. To directly test these assumptions, we engineered mice with AGT that
represented either extreme, namely disulfide bridge versus unbridged ratios being 0:100
or 100:0 (i.e complete absence versus complete presence of disulfide bridge).
Therefore, this approach provided an optimal condition for defining the contribution of
the disulfide bridge within AGT to blood pressure responses, and other indexes of AGTrenin reaction such as atherosclerosis.

Finally, the role of the disulfide bridge in regulating AGT cleavage is only relevant in
tissues (local) where prorenin receptors are present, while hepatic AGT, secreted into
circulation, is considered systemic. The study by Nguyen et al (169) is cited by Zhou et
al (11), in reference to a role for the prorenin receptors as a regulator of the interaction
between AGT and renin. It is worth noting that Nguyen et al (169) concluded that only
1% of soluble renin binds to prorenin receptors. This study and follow up studies (170,
171) have indicated that prorenin receptors have marginal effects in vivo on AngII
release and AngII-mediated effects. The Kd of prorenin receptors for renin has been
determined at 5-20 nmol/l by several groups (169-171). Zhou et al (11) was able to
demonstrate the presence of prorenin receptors lowered Km for the interaction of
oxidized AGT with renin at 0.1nM. Although renin concentrations in plasma are in the
picomolar range, renin concentrations in tissues may be 100-fold greater (169). The in
vitro data obtained by Zhou et al encouraged us to test their proposal in vivo. In fact,
mice express prorenin receptors in several tissues, including renal tissue as proposed by
Zhou et al (11). A recent study has provided convincing evidence that liver-derived AGT
(but not renal AGT) is the primary source of renal production of AngII that regulates
blood pressure (36). Therefore, administration of AAV with liver-specific promoter driven
AGT expression of disulfide-bridged or unbridged forms to mice with liver-specific AGT
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deficiency would deliver AGT substrate to kidney. Any role of prorenin receptors to
facilitate the renin/AGT reaction in modulating blood pressure would be operative in our
in vivo study. The effect of AGT on atherosclerosis is also likely to be due to its cleavage
at a cellular level since renin in tissues determines lesion development as demonstrated
in our previous study (50). Taken together, we consider that two of our major end points,
blood pressure and atherosclerosis, are regulated by AGT cleavage at a cellular level
within tissues, rather than being a systemic effect.

Taken together, our in vivo system, utilizing hepAGT-/- mice and AAV vectors delivering
engineered AGT, is a valid model to pull out “refinements” related to redox status for
AGT. However, our data do not support an important role of a redox mediated disulfide
bridge for regulating the in vivo effects of AGT.

Conclusions
We developed a host of unique reagents and in vivo systems to explore the effects of
AGT inhibition on atherosclerosis and obesity, and the structure-function relationship of
the Cys18-Cys137 disulfide bridge in AGT. We found AGT deficiency prevented
atherosclerosis and obesity, and hepatic AGT was responsible for these effects. We
revealed the therapeutic potentials of AGT inhibition by demonstrating that weekly
administration of AGT ASO not only prevented but also regressed obesity. Now we are
exploring the mechanisms of AGT inhibition induced lean phenotype. We are excited by
a particular preliminary data suggesting global AGT deficiency (hypoAGT) may delay the
release of triglycerides from enterocytes, which has the potential to affect lipid
metabolism in metabolically active tissues like liver and brown adipose tissue. We will be
further examining the data before we could establish a molecular link between AGT and
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lipid metabolism, thereby facilitating the development of AGT inhibition as therapeutics
against obesity.

Copyright © CONGQING WU 2014
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